New prognostic factors and scoring system for patients with acute myeloid leukemia

Kuang,Ye; Wang,Yang; Cao,Xianghong; Peng,Chuanmei; Gao,Hui

doi:10.3892/ol.2021.13084

New prognostic factors and scoring system for patients with acute myeloid leukemia

Authors:
- Ye Kuang
- Yang Wang
- Xianghong Cao
- Chuanmei Peng
- Hui Gao
View Affiliations

Affiliations: Medical Laboratory, Yan'An Hospital, Kunming, Yunnan 650000, P.R. China
Published online on: October 11, 2021 https://doi.org/10.3892/ol.2021.13084
Article Number: 823
Copyright: © Kuang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute myeloid leukemia (AML) is a malignant disease originating from myeloid hematopoietic stem or progenitor cells. It is important to identify molecules associated with the prognosis of AML and conduct an individual risk assessment for different patients. In the present study, the RNA expression profile of 132 patients with AML and 337 healthy individuals were downloaded from the University of California Santa Cruz Xena and the Genotype‑Tissue Expression project databases. Differentially expressed mRNA (DEmRNA) transcripts between normal blood and AML blood were identified. Among these, prognosis‑associated signature mRNA molecules were screened using univariate Cox and least absolute shrinkage and selection operator regression. A total of four genes, namely, family with sequence similarity 124 member B (FAM124B), 4‑hydroxyphenylpyruvate dioxygenase‑like protein (HPDL), myeloperoxidase (MPO) and purinergic receptor P2Y1 (P2RY1), were identified using multivariate Cox regression analysis and were used to construct a prognostic scoring system. Moreover, the expression levels of HPDL and MPO were higher in the samples with high immunity scores and estimate scores (sum of stromal score and immune score), compared with those with low scores. Reverse transcription‑quantitative PCR and western blot analysis were used to confirm the upregulation of the four candidate genes in AML cell lines as well as in clinical AML samples. In summary, the present study identified a novel mRNA‑based prognostic risk scoring system for patients with AML. The four genes used in this scoring system may also play an important role in AML.

View Figures

View References

1	Pelcovits A and Niroula R: Acute myeloid leukemia: A review. R I Med J (2013). 103:38–40. 2020.
2	De Kouchkovsky I and Abdul-Hay M: ‘Acute myeloid leukemia: A comprehensive review and 2016 update’. Blood Cancer J. 6:e4412016. View Article : Google Scholar
3	Rose-Inman H and Kuehl D: Acute leukemia. Emerg Med Clin North Am. 32:579–596. 2014. View Article : Google Scholar
4	Narayanan D and Weinberg OK: How I investigate acute myeloid leukemia. Int J Lab Hematol. 42:3–15. 2020. View Article : Google Scholar
5	Infante MS, Piris MÁ and Hernández-Rivas JÁ: Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications. Med Clin (Barc). 151:362–367. 2018.(In English, Spanish). View Article : Google Scholar
6	Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424–447. 2017. View Article : Google Scholar
7	Medeiros BC: Is there a standard of care for relapsed AML? Best Pract Res Clin Haematol. 31:384–386. 2018. View Article : Google Scholar
8	Daver N, Schlenk RF, Russell NH and Levis MJ: Targeting FLT3 mutations in AML: Review of current knowledge and evidence. Leukemia. 33:299–312. 2019. View Article : Google Scholar
9	Fernandez S, Desplat V, Villacreces A, Guitart AV, Milpied N, Pigneux A, Vigon I, Pasquet JM and Dumas PY: Targeting tyrosine kinases in acute myeloid leukemia: Why, who and how? Int J Mol Sci. 20:34292020. View Article : Google Scholar
10	Li K, Wang F and Hu ZW: Targeting TRIB3 and PML-RARα interaction against APL. Oncotarget. 8:52012–52013. 2017. View Article : Google Scholar
11	Sportoletti P, Celani L, Varasano E, Rossi R, Sorcini D, Rompietti C, Strozzini F, Del Papa B, Guarente V, Spinozzi G, et al: GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations. Leukemia. 33:1827–1832. 2019. View Article : Google Scholar
12	Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, et al: FTO plays an oncogenic role in acute myeloid leukemia as a N⁶-Methyladenosine RNA demethylase. Cancer Cell. 31:127–141. 2017. View Article : Google Scholar
13	Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, et al: R-2HG exhibits anti-tumor activity by targeting FTO/m⁶A/MYC/CEBPA signaling. Cell. 172:90–105.e23. 2018. View Article : Google Scholar
14	Damen JA, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I, Lassale CM, Siontis GC, Chiocchia V, Roberts C, et al: Prediction models for cardiovascular disease risk in the general population: Systematic review. BMJ. 353:i24162016. View Article : Google Scholar
15	Alaa AM, Bolton T, Di Angelantonio E, Rudd JH and van der Schaar M: Cardiovascular disease risk prediction using automated machine learning: A prospective study of 423,604 UK Biobank participants. PLoS One. 14:e02136532019. View Article : Google Scholar
16	Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT and Kathiresan S: Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 50:1219–1224. 2018. View Article : Google Scholar
17	Campbell DD, Li Y and Sham PC: Multifactorial disease risk calculator: Risk prediction for multifactorial disease pedigrees. Genet Epidemiol. 42:130–133. 2018. View Article : Google Scholar
18	Wang Z, Jensen MA and Zenklusen JC: A practical guide to The Cancer Genome Atlas (TCGA). Methods Mol Biol. 1418:111–141. 2016. View Article : Google Scholar
19	eGTEx Project: Enhancing GTEx by bridging the gaps between genotype, gene expression, and disease. Nat Genet. 49:1664–1670. 2017. View Article : Google Scholar
20	Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 33:451–458. 1976. View Article : Google Scholar
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2011. View Article : Google Scholar
22	Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, et al: Cancer and leukemia group B; German AML cooperative group. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 112:4193–4201. 2008. View Article : Google Scholar
23	Wang H, Wu X and Chen Y: Stromal-immune score-based gene signature: A prognosis stratification tool in gastric cancer. Front Oncol. 9:12122019. View Article : Google Scholar
24	Wojcicki AV, Kasowski MM, Sakamoto KM and Lacayo N: Metabolomics in acute myeloid leukemia. Mol Genet Metab. 130:230–238. 2020. View Article : Google Scholar
25	Seth R and Singh A: Leukemias in children. Indian J Pediatr. 82:817–824. 2015. View Article : Google Scholar
26	Skarsgård LS, Andersson MK, Persson M, Larsen AC, Coupland SE, Stenman G and Heegaard S: Clinical and genomic features of adult and paediatric acute leukaemias with ophthalmic manifestations. BMJ Open Ophthalmol. 4:e0003622019. View Article : Google Scholar
27	Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, et al: Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 374:2209–2221. 2016. View Article : Google Scholar
28	Klepin HD, Rao AV and Pardee TS: Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 32:2541–2552. 2014. View Article : Google Scholar
29	Yang JJ, Park TS and Wan TS: Recurrent cytogenetic abnormalities in acute myeloid leukemia. Methods Mol Biol. 1541:223–245. 2017. View Article : Google Scholar
30	Kayser S and Levis MJ: Clinical implications of molecular markers in acute myeloid leukemia. Eur J Haematol. 102:20–35. 2019. View Article : Google Scholar
31	Yang X, Wong MP and Ng RK: Aberrant DNA methylation in acute myeloid leukemia and its clinical implications. Int J Mol Sci. 20:45762019. View Article : Google Scholar
32	Li L, Lee KM, Han W, Choi JY, Lee JY, Kang GH, Park SK, Noh DY, Yoo KY and Kang D: Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet. 19:4273–4277. 2010. View Article : Google Scholar
33	Ghosh SG, Lee S, Fabunan R, Chai G, Zaki MS, Abdel-Salam G, Sultan T, Ben-Omran T, Alvi JR, McEvoy-Venneri J, et al: Biallelic variants in HPDL, encoding 4-hydroxyphenylpyruvate dioxygenase-like protein, lead to an infantile neurodegenerative condition. Genet Med. 23:524–533. 2021. View Article : Google Scholar
34	Ye X, Wei X, Liao J, Chen P, Li X, Chen Y, Yang Y, Zhao Q, Sun H, Pan L, et al: 4-Hydroxyphenylpyruvate dioxygenase-like protein promotes pancreatic cancer cell progression and is associated with glutamine-mediated redox balance. Front Oncol. 10:6171902021. View Article : Google Scholar
35	Reiding KR, Franc V, Huitema MG, Brouwer E, Heeringa P and Heck AJ: Neutrophil myeloperoxidase harbors distinct site-specific peculiarities in its glycosylation. J Biol Chem. 294:20233–20245. 2019. View Article : Google Scholar
36	Yuzhalin AE and Kutikhin AG: Common genetic variants in the myeloperoxidase and paraoxonase genes and the related cancer risk: A review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 30:287–322. 2012. View Article : Google Scholar
37	von Kügelgen I and Wetter A: Molecular pharmacology of P2Y-receptors. Naunyn Schmiedebergs Arch Pharmacol. 362:310–323. 2000. View Article : Google Scholar
38	Michael IP, Saghafinia S and Hanahan D: A set of microRNAs coordinately controls tumorigenesis, invasion, and metastasis. Proc Natl Acad Sci USA. 116:24184–24195. 2019. View Article : Google Scholar